Gökmen-Polar Y - Search Results

1

Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.

Duchnowska R, Jassem J, Goswami CP, Dundar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska-Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW Jr, Steeg PS, Badve S. Duchnowska R, et al. J Neurooncol. 2015 Mar;122(1):205-16. doi: 10.1007/s11060-014-1704-y. Epub 2015 Jan 6. J Neurooncol. 2015. PMID: 25559688 Free PMC article.

2

Protein kinase C-beta as a therapeutic target in breast cancer.

Sledge GW Jr, Gökmen-Polar Y. Sledge GW Jr, et al. Semin Oncol. 2006 Jun;33(3 Suppl 9):S15-8. doi: 10.1053/j.seminoncol.2006.03.019. Semin Oncol. 2006. PMID: 16797377 Review.

3

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.

Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2010 Nov;124(2):327-35. doi: 10.1007/s10549-010-0733-2. Epub 2010 Jan 23. Breast Cancer Res Treat. 2010. PMID: 20099025

4

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Gökmen-Polar Y, et al. Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3. Breast Cancer Res Treat. 2011. PMID: 20602165

5

Tumor marker assessment: points to ponder.

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Cancer Biol Ther. 2011 Jan 15;11(2):284-6. doi: 10.4161/cbt.11.2.14370. Epub 2011 Jan 15. Cancer Biol Ther. 2011. PMID: 21178400 No abstract available.

6

Biomarkers for breast cancer stem cells: the challenges ahead.

Gökmen-Polar Y, Nakshatri H, Badve S. Gökmen-Polar Y, et al. Biomark Med. 2011 Oct;5(5):661-71. doi: 10.2217/bmm.11.57. Biomark Med. 2011. PMID: 22003917 Review.

7

Molecular profiling assays in breast cancer: are we ready for prime time?

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Oncology (Williston Park). 2012 Apr;26(4):350-7, 361. Oncology (Williston Park). 2012. PMID: 22655528 Free article. Review.

8

Molecular analysis of thymoma.

Badve S, Goswami C, Gökmen-Polar Y, Nelson RP Jr, Henley J, Miller N, Zaheer NA, Sledge GW Jr, Li L, Kesler KA, Loehrer PJ Sr. Badve S, et al. PLoS One. 2012;7(8):e42669. doi: 10.1371/journal.pone.0042669. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912720 Free PMC article.

9

Establishment and characterization of a novel cell line derived from human thymoma AB tumor.

Gökmen-Polar Y, Sanders KL, Goswami CP, Cano OD, Zaheer NA, Jain RK, Kesler KA, Nelson RP Jr, Vance GH, Smith D, Li L, Cardoso AA, Badve S, Loehrer PJ Sr, Sledge GW Jr. Gökmen-Polar Y, et al. Lab Invest. 2012 Nov;92(11):1564-73. doi: 10.1038/labinvest.2012.115. Epub 2012 Aug 27. Lab Invest. 2012. PMID: 22926645 Free article.

10

Breast cancer prognostic markers: where are we now?

Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. MLO Med Lab Obs. 2012 Sep;44(9):22, 24-5. MLO Med Lab Obs. 2012. PMID: 23002506 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page